Article ID Journal Published Year Pages File Type
3975427 Taiwanese Journal of Obstetrics and Gynecology 2012 6 Pages PDF
Abstract

ObjectiveAmniocentesis is a popular and effective prenatal diagnostic tool for chromosomal disorders. It is well-established that the risk of chromosomal abnormalities increases with maternal age; however, other related indications are seldom reported. Herein, we report our 30-year experience with amniocentesis from a single medical center, focusing on the indications and rates of abnormality.Material and MethodsA retrospective review of 16,749 pregnant women in the mid-trimester between January 1981 and December 2010 was conducted. The medical records were analyzed.ResultsThe indications for amniocentesis were advanced maternal age (≥ 34 years old) (n = 10,970, 65.5%), increasing-risk maternal triple-marker Down's screening test (≥ 1/270) (n = 2090, 12.5%), history of abnormal offspring birth (n = 792, 4.7%), abnormal ultrasound findings (n = 484, 2.9%), parent with abnormal karyotype (n = 252, 1.5%), family history of chromosomal abnormality (n = 183, 1.1%), drug and radiation exposure (n = 165), abnormal chorionic villus sampling (CVS) results (n = 25), intrauterine fetal death (n = 50), and other non-specific causes (n = 1662, 9.9%). The rate of abnormality for each indication was 16% in the abnormal CVS group, 12% in the intrauterine fetal death group, 11.5% for parental chromosomal abnormality, 8.7% in the abnormal ultrasound finding group, 3.0% in the increasing-risk maternal triple-marker Down's screening test group, 2.5% in the advanced maternal age group, 1.5% for other non-specific causes, 1.4% for history of abnormal offspring birth, and 1.1% for family history of chromosomal abnormality.ConclusionsBoth parents with abnormal karyotype and abnormal ultrasound findings are indications for which consideration of further amniocentesis is highly recommended.

Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Authors
, , , , , , , , , , , , ,